MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
TopiVert
Parents
*Architects: Biotechnology_Immunotherapy & Inflammation
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
*Architects: Ophthalmology, Optometry & Ocular Health (BioPharmaceuticals & Biotechnology)
*Industry: United Kingdom - UK (England, Scotland, Wales, Northern Ireland)
Venture Capital: Series A
Children
Amt: 12.52M Round: Series A Investor(s) Imperial Innovations Group, SV Life Sciences (2011)
Series A $12.5M by OnBioVC (2012)
TopiVert is developing topical medicines for inflammatory diseases of the eye and gut.